title: [Long-term prognostic analysis of patients with malignant pleural mesothelioma].
abstract: OBJECTIVE
  Malignant pleural mesothelioma (MPM) is a rare disease with poor prognosis. This study was to analyze long-term results, and prognostic factors of patients with MPM.
  
  
  METHODS
  Records of 24 patients with MPM, proved by pathology or cytology, treated in our hospital from Jan. 1988 to Dec. 2001 were analyzed retrospectively. Of the 24 patients, 12 received chemotherapy alone (1-6 cycles of cisplatin-based regimens), 7 received surgery plus postoperative chemotherapy (1-6 cycles of cisplatin-based regimens), and 5 received surgery plus postoperative radiotherapy. Kaplan-Meier method and log-rank test were used to evaluate the survival rates. Cox regression model was used to explore prognostic factors of MPM.
  
  
  RESULTS
  Of the 24 patients, 1-, 3-, and 5-year survival rates were 37.5%, 20.8%, and 4.2%, respectively,with a median survival time of 9 months; those in chemotherapy group were 16.7%, 0, and 0, respectively, with a median survival time of 5 months; in surgery plus chemotherapy group were 28.6%, 14.3%, and 0, respectively, with a median survival time of 10 months; in surgery plus radiotherapy group were 100.0%, 80.0%, and 20.0%, respectively, with a median survival time of 42 months. There were significant differences among 3 groups (Chi(2)=11.93, P =0.002). Multivariate analysis showed that clinical classification (P=0.038), and mode of treatment (P=0.005) were independent prognostic factors of MPM.
  
  
  CONCLUSIONS
  Mode of treatment, and clinical classification are independent prognostic factors for patients with MPM.
authors.affiliation: Department of Radiotherapy, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong 510-060, P.R. China. caokajia@163.com
authors.forename: Ka-Jia
authors.initials: KJ
authors.lastname: Cao
authors.forename: Nian-Ji
authors.initials: NJ
authors.lastname: Cui
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000556:secondary / Q000601:surgery / Q000628:therapy*; D008875:Middle Aged; D010997:Pleural Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D011013:Pneumonectomy; D011379:Prognosis; D016016:Proportional Hazards Models; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin